The specificity of binding studies performed with IR700-Atezolizumab demonstrated complementary median fluorescence intensity (MFI) of IR700-Atezolizumab with PD-L1 expression levels measured in a panel of human and murine GBM cells. The gene discussed is CD274; the disease is glioblastoma.